Phibro Animal Health (NASDAQ:PAHC) Cut to "Hold" at StockNews.com

Market Beat
2025.03.09 04:09
portai
I'm PortAI, I can summarize articles.

Phibro Animal Health (NASDAQ:PAHC) has been downgraded from a "buy" to a "hold" rating by StockNews.com. Other analysts have mixed views, with Barclays raising its price target to $22 and Morgan Stanley to $25. The stock is currently trading at $23.64, with a market cap of $957.49 million. Phibro reported earnings of $0.54 per share, exceeding estimates. Institutional investors hold 99.34% of the stock. Analysts forecast an EPS of 1.95 for the current fiscal year.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) was downgraded by equities research analysts at StockNews.com from a "buy" rating to a "hold" rating in a research note issued on Friday.

Get Phibro Animal Health alerts:

A number of other research analysts also recently commented on PAHC. Barclays upped their price objective on Phibro Animal Health from $20.00 to $22.00 and gave the stock an "underweight" rating in a research note on Monday, February 10th. Morgan Stanley upped their price objective on Phibro Animal Health from $20.00 to $25.00 and gave the company an "equal weight" rating in a report on Tuesday, December 17th. Two analysts have rated the stock with a sell rating and three have issued a hold rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $21.00.

Get Our Latest Stock Analysis on Phibro Animal Health

Phibro Animal Health Stock Performance

Shares of NASDAQ PAHC traded up $0.33 during trading on Friday, reaching $23.64. The stock had a trading volume of 339,958 shares, compared to its average volume of 253,645. Phibro Animal Health has a one year low of $11.98 and a one year high of $26.55. The company has a debt-to-equity ratio of 2.99, a quick ratio of 1.37 and a current ratio of 3.20. The stock has a market cap of $957.49 million, a PE ratio of 49.25, a P/E/G ratio of 0.45 and a beta of 0.52. The firm's 50 day moving average price is $22.47 and its two-hundred day moving average price is $22.48.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.54 earnings per share for the quarter, beating analysts' consensus estimates of $0.40 by $0.14. Phibro Animal Health had a return on equity of 25.35% and a net margin of 1.75%. On average, research analysts forecast that Phibro Animal Health will post 1.95 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of PAHC. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Phibro Animal Health during the 4th quarter worth about $29,000. Lazard Asset Management LLC boosted its stake in shares of Phibro Animal Health by 2,739.7% during the 4th quarter. Lazard Asset Management LLC now owns 1,647 shares of the company's stock worth $34,000 after acquiring an additional 1,589 shares in the last quarter. Quantbot Technologies LP bought a new stake in shares of Phibro Animal Health during the 3rd quarter worth about $70,000. Virtus Fund Advisers LLC bought a new stake in shares of Phibro Animal Health during the 4th quarter worth about $69,000. Finally, Aquatic Capital Management LLC bought a new stake in shares of Phibro Animal Health during the 4th quarter worth about $69,000. 99.34% of the stock is owned by institutional investors and hedge funds.

About Phibro Animal Health

(Get Free Report)

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.

Featured Stories

  • Five stocks we like better than Phibro Animal Health
  • Consumer Staples Stocks, Explained
  • Is Myers Industries Poised for a Breakout?
  • The How and Why of Investing in Gold Stocks
  • Is BigBear.ai's 25% Plunge a False Alarm or Fire Sale?
  • What Are Dividends? Buy the Best Dividend Stocks
  • Broadcom Confirmed Its AI Outlook: Stock to Hit New Highs Soon

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Phibro Animal Health Right Now?

Before you consider Phibro Animal Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phibro Animal Health wasn't on the list.

While Phibro Animal Health currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Source: Market Beat The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.